



Enhancing Corporate Value

Eisai Co., Ltd.

June 15, 2005

Please refer to the US Roadshow, June 2005 material in our WEB site for further information
<http://www.eisai.co.jp/eir/ematerials/index.html#1>

Safe Harbor Statement

- Materials and information provided during this presentation may contain “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements.
- Risks and uncertainties include general industry and market conditions, and general domestic and international economic conditions such as interest rate and currency exchange fluctuations. Risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, technological advances and patents attained by competitors, challenges inherent in new product development, including completion of clinical trials; claims and concerns about product safety and efficacy; obtaining regulatory approvals; domestic and foreign healthcare reforms; trends toward managed care and healthcare cost containment, and governmental laws and regulations affecting domestic and foreign operations.
- Also, for products that are approved, there are manufacturing and marketing risks and uncertainties, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials, and failure to gain market acceptance.
- The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Eisai's R&D Strengths

- **Two recent success of Proof-Of-Concept studies; E2007 (Parkinson's disease) and E7389 (cancer)**

Two Recent Success of Proof of Concept Studies

Mode of Action

AMPA Receptor Antagonist

Microtubule Growth Suppressor

- Excellent safety profile
- No worsening of dyskinesia (PD)

No major drug-drug interactions

Once a day, oral administration

Formulation

Small tablets

Vials (solution)

Target submission date

FY2006

FY2006

Enriching Pipeline (New Molecular Entities)

Project	Stage	Mode of action	Target profile
Inovelon® - rufinamide (Epilepsy)	Pre-registration	Na ⁺ channel modulator	Adjunctive therapy for Lennox-Gastaut Syndrome, a severe disease with high unmet medical needs, as well as adult partial seizure
Agilect® - rasagiline (Parkinson's disease)	Pre-registration	MAO-B inhibition	Neuroprotective effect (Phase II for AD ongoing) Better safety profile than other MAO-B inhibitor
Careram® - igratimod (Rheumatoid arthritis)	Pre-registration	Cytokine/Immunoglobulin suppression	Similar efficacy to salazosulfapyridine, a standard drug for RA Better safety profile with fewer severe adverse effects
Sibutramine (Obesity Management)	Phase III	Serotonin/Noradrenarin reuptake inhibition	Natural body weight loss based on dual actions of appetite suppression and energy consumption increase
Adalimumab (Rheumatoid arthritis)	Phase II/III	Anti-TNF antibody	Strong and long-lasting efficacy for RA symptoms Monotherapy or combination with methotrexate
E2007 (Parkinson's disease)	Phase III	AMPA receptor antagonist	Reduction of Off-Time in PD by adjunct therapy with levodopa Excellent safety profile, No worsening of dyskinesia
E0167 (Hepatocellular carcinoma)	Phase II/III	Vitamin K ₂	Reduce recurrence of hepatocellular carcinoma
Clevudine (Hepatitis B)	Phase III	HBV polymerase inhibition	Less rebound than existing anti-viral agent
E7389 (Cancer)	Phase II	Microtubule growth suppression	Better anticancer efficacy than taxanes Good tolerability, less neurotoxicity
E7070 (Cancer)	Phase II	G1 Phase targeting	Different anticancer spectrum from existing cytotoxics
E5564 (Sepsis, CABG)	Phase II	Endotoxin antagonist	Reduce mortality and morbidity, Good safety profile
E5555 (Prevention of major cardiac events)	Phase I	Thrombin receptor antagonist	Dual action of anti-platelet and smooth muscle cell proliferation inhibition
E7820 (Cancer)	Phase I	α2 integrin suppression	Survival benefit due to chronic tumor growth suppression
E7080 (Cancer)	Phase I	VEGFR kinase inhibition	Survival benefit due to chronic tumor growth suppression
E7974 (Cancer)	Phase I	Tubulin inhibition	Effective in multi-drug resistant tumors

Opportunities in Key Areas/Countries⁵



▫



**US
Sales**

